Comparison · NCT04939428-320c4583
Molnupiravir vs Placebo: Percentage of Participants With ≥1 Adverse Event
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Molnupiravir vs Placebo: Percentage of Participants With ≥1 Adverse Event. Trial comparisons, record NCT04939428-320c4583. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04939428-320c4583
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.123 | 0.102 | 0.148 | wilson | |
| Risk in group 2 | 0.137 | 0.115 | 0.163 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0141 | -0.0479 | 0.0198 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.898 | 0.692 | 1.16 | log | |
| Odds ratio, group 1 over group 2 | 0.883 | 0.655 | 1.19 | log | |
| Number needed to treat, for one fewer participant with the outcome on Molnupiravir than on Placebo | 71.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Molnupiravir | Participants were treated with molnupiravir 800 mg every 12 hours (Q12H) on Days 1 to 5. | 94 | 763 | OG000 |
| Group 2 | Placebo | Participants were given placebo Q12H on Days 1 to 5. | 105 | 765 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Percentage of Participants With ≥1 Adverse Event
- Description
- An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Time frame
- 29 days
- Population
Safety Analyses was conducted in the APaT population, which consists of all randomized participants who received at least 1 dose of study intervention. Index participants were not included in OM analysis per protocol.
Source ClinicalTrials.gov
Trial
- Title
- Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
- NCT number
- NCT04939428
- Phases
- PHASE3
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Molnupiravir, Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2024-02-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04939428?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04939428-320c4583